Unknown

Dataset Information

0

Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes.


ABSTRACT: EGF and gastrin co-administration reverses type 1 diabetes in rodent models. However, the failure of this to translate into a clinical treatment suggests that EGF-mediated tissue repair is a complicated process and warrants further investigation. Thus, we aimed to determine whether EGF receptor (EGFR) feedback inhibition by mitogen-inducible gene 6 protein (MIG6) limits the effectiveness of EGF therapy and promotes type 1 diabetes development.We treated Mig6 (also known as Errfi1) haploinsufficient mice (Mig6 (+/-)) and their wild-type littermates (Mig6 (+/+)) with multiple low doses of streptozotocin (STZ), and monitored diabetes development via glucose homeostasis tests and histological analyses. We also investigated MIG6-mediated cytokine-induced desensitisation of EGFR signalling and the DNA damage repair response in 832/13 INS-1 beta cells.Whereas STZ-treated Mig6 (+/+) mice became diabetic, STZ-treated Mig6 (+/-) mice remained glucose tolerant. In addition, STZ-treated Mig6 (+/-) mice exhibited preserved circulating insulin levels following a glucose challenge. As insulin sensitivity was similar between Mig6 (+/-) and Mig6 (+/+) mice, the preserved glucose tolerance in STZ-treated Mig6 (+/-) mice probably results from preserved beta cell function. This is supported by elevated Pdx1 and Irs2 mRNA levels in islets isolated from STZ-treated Mig6 (+/-) mice. Conversely, MIG6 overexpression in isolated islets compromises glucose-stimulated insulin secretion. Studies in 832/13 cells suggested that cytokine-induced MIG6 hinders EGFR activation and inhibits DNA damage repair. STZ-treated Mig6 (+/-) mice also have increased beta cell mass recovery.Reducing Mig6 expression promotes beta cell repair and abates the development of experimental diabetes, suggesting that MIG6 may be a novel therapeutic target for preserving beta cells.

SUBMITTER: Chen YC 

PROVIDER: S-EPMC4156529 | biostudies-other | 2014 Oct

REPOSITORIES: biostudies-other

altmetric image

Publications

Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes.

Chen Yi-Chun YC   Colvin E Scott ES   Griffin Katherine E KE   Maier Bernhard F BF   Fueger Patrick T PT  

Diabetologia 20140704 10


<h4>Aims/hypothesis</h4>EGF and gastrin co-administration reverses type 1 diabetes in rodent models. However, the failure of this to translate into a clinical treatment suggests that EGF-mediated tissue repair is a complicated process and warrants further investigation. Thus, we aimed to determine whether EGF receptor (EGFR) feedback inhibition by mitogen-inducible gene 6 protein (MIG6) limits the effectiveness of EGF therapy and promotes type 1 diabetes development.<h4>Methods</h4>We treated Mi  ...[more]

Similar Datasets

| S-EPMC5073304 | biostudies-literature
| S-EPMC5020504 | biostudies-literature
| S-EPMC8410679 | biostudies-literature
| S-EPMC6204188 | biostudies-literature
| S-EPMC4302753 | biostudies-literature
| S-EPMC2877934 | biostudies-literature
| S-EPMC4709037 | biostudies-literature
| S-EPMC7835906 | biostudies-literature
| S-EPMC4084867 | biostudies-literature
| S-EPMC7227011 | biostudies-literature